2 FTSE 100 stocks I’d buy after October’s big sell-off

Share price falls of 8% and 10% make these two FTSE 100 (INDEXFTSE:UKX) stocks great value, says G A Chester.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Whitbread (LSE: WTB) and Smiths Group (LSE: SMIN) are two blue-chip stocks that have fallen more heavily than the FTSE 100 in the October sell-off. As I’m writing, the index is down a bit over 6%, while Whitbread and Smiths have fallen around 8% and 10%, respectively. I thought these two stocks were good value before the sell-off, so I’d be more than happy to buy them at their current discount prices.

Costa bravo

Back in midsummer, when Whitbread’s shares were trading at 3,893p (valuing the group at £7.15bn), I reckoned a fair sum-of-the-parts valuation was 5,200p (£9.55bn). Management had made a commitment to demerge Costa Coffee and I liked the long-term outlook for both Costa and Whitbread’s other business, Premier Inn. I also reckoned there was a fair chance of a value-outing takeover bid coming in for Costa before the demerger.

At the end of August, Whitbread announced an agreement to sell Costa to The Coca-Cola Company for £3.9bn. The shares leapt 14% on the day and went on to reach a high of 4,728p, before retreating to their current level of 4,346p. I’m still confident Whitbread’s shares deserve to trade comfortably above 5,000p — and that they will do so in due course.

Premier growth

The sale of Costa is expected to complete in the first half of 2019, with Coca-Cola needing to obtain regulatory approval in the EU and China. This shouldn’t be a problem and Whitbread is expecting net cash proceeds of £3.8bn from the sale, after transaction costs and separation costs. This will give the company considerable firepower to continue growing Premier Inn’s core UK business and to expand at scale internationally.

Given the size of the growth opportunity I see here, I view a current-year forecast price-to-earnings (P/E) ratio of 17.5, and running dividend yield of 2.3%, as offering excellent long-term value. And I wouldn’t rule out a bid for Premier Inn in the short term either.

Evolution or revolution

Industrial conglomerate Smiths is another company with value-outing break-up potential. Indeed, with five operating divisions and multiple businesses serving all manner of markets, the potential is considerable.

The current management team has focused on evolution rather than revolution but is evidently not averse to more radical restructuring. US firm ICU Medical tabled an offer for Smiths’ medical division earlier this year. The board ultimately rejected it, but the valuation put on just this one division by ICU — between £2.5bn and £2.8bn, according to Sky News — hints at the value that could be unlocked by a break-up or partial break-up of the conglomerate. The stock market is valuing the whole Smiths group at £5.4bn (at a current share price of 1,361p), and I’m confident this is well below the sum of the parts.

The company currently trades on a forecast P/E of 13.9 and running dividend yield of 3.3%. I view this as an attractive valuation for the evolving business but would hope to see an acceleration in the outing of value by more radical restructuring. On this front, I take a positive view of Smiths’ announcement last week that it’s appointed Goldman Sachs –which had advised it in its discussions with ICU — as joint corporate broker.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »